Definium Therapeutics
DFTX
35.09
-0.53
-1.49%
Definium Therapeutics
US · DFTX
#2132 by market cap
Listed 1970
35.09
-0.53
-1.49%
Live - 5344 symbols - heartbeat 348s ago
· 2026-10-08 07:26
Pre-market
34.74
-1.00%
After-hours
35.07
-0.06%
Overnight
35.86
+2.19%
- Market cap
- 4.71B
- P/E (TTM)i
- -10.23
- P/Bi
- 5.13
- EPSi
- -2.06
- Div yieldi
- 0.00%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on DFTX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 14.40M | 59.07M | 30.16M | 41.74M | 38.62M | 48.64M |
| Research & development | 18.63M | 34.79M | 36.17M | 52.12M | 65.30M | 117.67M |
| Operating profit | -33.03M | -93.85M | -66.33M | -93.87M | -103.92M | -166.31M |
| Pretax profit | -33.94M | -94.19M | -56.80M | -95.73M | -108.68M | -183.79M |
| Tax | 0 | -1.16M | -- | -- | -- | -- |
| Net profit | -33.94M | -93.04M | -56.80M | -95.73M | -108.68M | -183.79M |
| Basic EPS | -2 | -3 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.95 | -3.40 | -1.84 | -2.44 | -1.54 | -2.06 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.80M | 11.09M | 14.69M | 14.06M | 17.74M | 26.41M |
| Research & development | 23.36M | 29.81M | 30.98M | 33.52M | 41.48M | 48.67M |
| Operating profit | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M | -75.08M |
| Pretax profit | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M | -158.99M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M | -158.99M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.35 | -0.50 | -0.78 | -0.50 | -0.71 | -1.44 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 81.52M | 137.22M | 146.06M | 103.87M | 281.62M | 419.32M |
| Cash & ST investments | 80.09M | 133.54M | 142.14M | 99.70M | 273.74M | 411.59M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 81.52M | 164.00M | 169.99M | 124.54M | 302.15M | 440.10M |
| Total current liabilities | 3.01M | 10.41M | 17.89M | 32.25M | 38.85M | 66.70M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | 14.13M | 21.85M | 40.58M |
| Total liabilities | 5,651,000.00 | 12,338,000.00 | 19,076,000.00 | 46,407,000.00 | 60,703,000.00 | 107,773,000.00 |
| Total equity | 75.87M | 151.66M | 150.92M | 78.13M | 241.45M | 332.33M |
| Retained earnings | -44.64M | -137.67M | -194.47M | -290.20M | -398.88M | -582.67M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 221.70M | 189.14M | 215.85M | 419.32M | 380.56M | 1.09B |
| Cash & ST investments | 212.44M | 182.99M | 209.07M | 411.59M | 373.42M | 1.08B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 275.32M | 265.09M | 236.92M | 440.10M | 401.29M | 1.11B |
| Total current liabilities | 30.48M | 37.96M | 65.42M | 66.70M | 81.11M | 157.20M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 22.04M | 41.19M | 40.39M | 40.58M | 40.77M | 36.47M |
| Total liabilities | 52,517,000.00 | 79,691,000.00 | 106,320,000.00 | 107,773,000.00 | 122,444,000.00 | 194,220,000.00 |
| Total equity | 222.81M | 185.40M | 130.60M | 332.33M | 278.85M | 918.68M |
| Retained earnings | -422.23M | -464.97M | -532.24M | -582.67M | -659.77M | -818.76M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -23.60M | -45.82M | -50.14M | -64.37M | -79.13M | -131.56M |
| Depreciation & amortization | 0 | 2.62M | 3.18M | 3.16M | 527.00K | 0 |
| Free cash flow | -23.60M | -45.82M | -50.14M | -64.37M | -79.13M | -131.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 71.99M | 81.92M | 42.30M | 0 | 250.98M | 258.86M |
| Ending cash balance | 80.09M | 133.54M | 142.14M | 99.70M | 273.74M | 257.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -29.42M | -29.60M | -29.57M | -42.98M | -42.63M | -52.78M |
| Depreciation & amortization | -- | -- | -- | 0 | -- | -- |
| Free cash flow | -29.42M | -29.60M | -29.57M | -42.98M | -42.63M | -52.78M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 186.00K | -186.00K | 0 | 258.86M | 276.00K | 804.72M |
| Ending cash balance | 82.85M | 33.39M | 19.96M | 257.84M | 262.52M | 655.27M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -44.73 | -81.78 | -37.54 | -83.59 | -68.01 | -64.06 |
| ROA %i | -41.63 | -75.79 | -34.01 | -65.01 | -50.94 | -49.52 |
| ROIC %i | -44.52 | -81.47 | -37.52 | -74.41 | -66.35 | -59.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -63.13 | -67.00 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 27.10 | 13.18 | 8.16 | 3.22 | 7.25 | 6.29 |
| Quick ratioi | 26.63 | 12.83 | 7.94 | 3.09 | 7.05 | 6.17 |
| Debt / assetsi | -- | 0.00 | -- | 11.34 | 7.23 | 9.22 |
| LT debt / equityi | -- | -- | -- | 18.08 | 9.05 | 12.21 |
| Interest coveragei | -205.93 | -261.38 | -- | -- | -46.60 | -32.53 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -37.07 | -59.11 | -85.59 | -64.06 | -94.70 | -64.09 |
| ROA %i | -28.18 | -42.95 | -60.39 | -49.52 | -70.22 | -51.35 |
| ROIC %i | -38.46 | -53.96 | -76.06 | -59.50 | -86.24 | -61.19 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.27 | 4.98 | 3.30 | 6.29 | 4.69 | 6.95 |
| Quick ratioi | 6.97 | 4.82 | 3.20 | 6.17 | 4.60 | 6.89 |
| Debt / assetsi | 8.00 | 15.54 | 17.05 | 9.22 | 10.16 | 3.28 |
| LT debt / equityi | 9.89 | 22.22 | 30.92 | 12.21 | 14.62 | 3.97 |
| Interest coveragei | -30.67 | -25.49 | -33.52 | -32.53 | -37.78 | -69.48 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:26:40 · For reference only, not investment advice and not tailored to your situation.